SBRT for HCC: Overview of technique and treatment response assessment

[1]  M. Schipper,et al.  Natural history of hepatocellular carcinoma after stereotactic body radiation therapy , 2020, Abdominal Radiology.

[2]  T. Fitzgerald,et al.  Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis , 2020, Advances in radiation oncology.

[3]  Junxin Wu,et al.  Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis , 2020, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[4]  Yue Cao,et al.  Individualized adaptive radiation therapy allows for safe treatment of hepatocellular carcinoma in patients with Child-Turcotte-Pugh B liver disease. , 2019, International journal of radiation oncology, biology, physics.

[5]  Jeffrey W. Clark,et al.  Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. , 2019, International journal of radiation oncology, biology, physics.

[6]  S. Gerum,et al.  Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review , 2019, World journal of gastrointestinal oncology.

[7]  T. Kim,et al.  Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls , 2019, Abdominal Radiology.

[8]  J. Seong,et al.  Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Y. Abbas,et al.  MRI assessment of hepatocellular carcinoma after locoregional therapy , 2019, Insights into Imaging.

[10]  A. Niemierko,et al.  Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma , 2019, American journal of clinical oncology.

[11]  Prasad R. Shankar,et al.  Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. , 2019, International journal of radiation oncology, biology, physics.

[12]  L. Dawson,et al.  Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies , 2018, Technology in cancer research & treatment.

[13]  O. Matsui,et al.  Pathology and images of radiation-induced hepatitis: a review article , 2018, Japanese Journal of Radiology.

[14]  J. Tepper,et al.  A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  R. Ma,et al.  Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment. , 2018, The British journal of radiology.

[16]  Yong Hu,et al.  Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting , 2017, Liver Cancer.

[17]  H. Hussain,et al.  Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. , 2017, International journal of radiation oncology, biology, physics.

[18]  Xin Deng,et al.  Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma. , 2017, International journal of radiation oncology, biology, physics.

[19]  L. Dawson,et al.  Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. , 2017, Journal of hepatology.

[20]  A. Koong,et al.  Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. , 2017, Practical radiation oncology.

[21]  J. Lacy,et al.  Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  J. Salleron,et al.  Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma , 2017, PloS one.

[23]  O. Riou,et al.  Evaluation of response after SBRT for liver tumors. , 2017, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[24]  M. Ychou,et al.  SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques. , 2017, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[25]  I. Hyodo,et al.  Long‐term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma , 2017, Cancer science.

[26]  Sang‐wook Lee,et al.  Gated Volumetric-Modulated Arc Therapy vs. Tumor-Tracking CyberKnife Radiotherapy as Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Dosimetric Comparison Study Focused on the Impact of Respiratory Motion Managements , 2016, PloS one.

[27]  Mary Feng,et al.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Lipika Goyal,et al.  Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Franco,et al.  Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma , 2016, La radiologia medica.

[30]  E. Kunieda,et al.  Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation , 2016, Cancer.

[31]  Eugene J Koay,et al.  Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance , 2016, Cancer.

[32]  S. Venkatesh,et al.  Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review , 2016, Abdominal Radiology.

[33]  Cynthia S. Johnson,et al.  Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. , 2015, Practical radiation oncology.

[34]  Myeong-Jin Kim,et al.  Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease , 2015, Clinical and molecular hepatology.

[35]  B. Siewert,et al.  CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors , 2015, Gastroenterology research and practice.

[36]  M. Scorsetti,et al.  The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT) , 2015, Journal of Cancer Research and Clinical Oncology.

[37]  L. Dawson,et al.  Radiation therapy for liver tumors: ready for inclusion in guidelines? , 2014, The oncologist.

[38]  A. Haynes,et al.  Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. , 2014, Practical radiation oncology.

[39]  S. Park,et al.  Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography , 2014, PloS one.

[40]  E. Kunieda,et al.  Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients , 2014, Acta oncologica.

[41]  E. Kunieda,et al.  Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. , 2013, AJR. American journal of roentgenology.

[42]  J. Balter,et al.  Stereotactic body radiation therapy for primary and metastatic liver tumors. , 2013, Translational oncology.

[43]  K. Chayama,et al.  Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: How should we evaluate treatment effects? , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[44]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Y. Jen,et al.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. , 2012, International journal of radiation oncology, biology, physics.

[46]  S. Yoo,et al.  Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[47]  T. Hong,et al.  Charged-particle therapy for hepatocellular carcinoma. , 2011, Seminars in radiation oncology.

[48]  S. Perkins,et al.  Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[49]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[50]  M. McCarter,et al.  Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[51]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[52]  Kazunori Kubota,et al.  Growth Rate of Primary Single Hepatocellular Carcinoma: Determining Optimal Screening Interval with Contrast Enhanced Computed Tomography , 2003, Digestive Diseases and Sciences.

[53]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[54]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[55]  Alexandria,et al.  Assessment of Hepatocellular Carcinoma after Local-Regional Therapy : A Comprehensive Review , 2020 .

[56]  E. Yorke,et al.  Radiation Dose-Volume Effects for Liver SBRT. , 2018, International journal of radiation oncology, biology, physics.

[57]  J. Sicklick,et al.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[58]  Kathryn J Fowler,et al.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm , 2017, Abdominal Radiology.

[59]  V. Mazzaferro,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, European journal of cancer.

[60]  一徳 久保田.  Growth rate of primary single hepatocellular carcinoma : determining optimal screening interval with contrast enhanced computed tomography , 2004 .